Ocular Therapeutix (OCUL) Misses Q4 EPS by 8c, Revenues Miss

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.53), $0.08 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $2.26 million versus the consensus estimate of $2.54 million.

“Ocular Therapeutix has had an impressive final quarter of 2019 and strong start to 2020,” said Antony Mattessich, President and Chief Executive Officer. “Key performance indicators on the launch of DEXTENZA point to a building momentum, most notably in the number of billable inserts ordered by ASC’s and hospitals that show a definitive acceleration. We are equally excited on the product development side by interim results from our two Phase 1 programs: in our OTX-TIC program, signals support the possibility for a product that could have both the magnitude and duration of effect to become a standard of care in the treatment of elevated IOP; and, most encouragingly, in our OTX-TKI program, we have seen a signal of biologic effect, observing a reduction in sub-retinal and intra-retinal fluid in some patients with wet AMD. Both of these early programs have the potential to shift current treatment paradigms.”

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Sinda raises $331M in IPO, reports Q2 net loss of $16.6M